Research page
CJC-1295 w DAC

Specification
| Name | CJC-1295 w DAC |
|---|---|
| Catalog sizes | 5 mg |
| Adopted bacteriostatic water | 5 mg + 2.0 mL = 2.5 mg/mL |
Overview
CJC-1295 with DAC is a long-acting GHRH analog in the literature. The TRACE vial is 5 mg. The study cited evaluated that long-acting form in healthy adults.
Mechanism under study
The DAC complex was studied because it prolongs the analog’s time in circulation. The 2006 paper described a rise in growth hormone and IGF-1 during that study’s window. It is not a schedule for this vial.
What published research has reported
TRACE cites the paper by Teichman and colleagues (2006) and does not add an amount for use. The vial is not an approved medicine.
Composition and mass
5 mg vial. Adopted bacteriostatic water: 2 mL (2.5 mg/mL).
Reconstitution
| mg | mL | mg/mL | |
|---|---|---|---|
| 5 | 2.0 | 2.5 | In the catalog |
Storage and handling
Lyophilized material cool, dry, and protected from light. Dissolved: 2–8 °C, not frozen, 28-day horizon.
Regulatory status
Research material. Not growth hormone and not an approved medicine.